Laura Chico


ANALYST BIOGRAPHY

Laura brings more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in Equity Research. During her career, Laura has served as Vice President Equity Research at Raymond James, and as a biotech analyst in the Robert W. Baird Equity Research Healthcare group. Before entering equity research, Laura held scientific roles in both industry and academic settings with focus in central nervous system (“CNS”) diseases such as Alzheimer’s disease.

Laura received her B.S. in Bacteriology from the University of Wisconsin-Madison, her M.S. in Computational Biology & Bioinformatics, and her Ph.D. in Molecular Pharmacology, from Northwestern University. She continues to serve as an adjunct assistant professor at Northwestern University’s Feinberg School of Medicine.

ANALYST EDGE

Laura’s Edge: Her combination of scientific, research, and academic communities experiences, gives Laura a deeper understanding and ability to translate complex data sets for investors.

COMPANIES UNDER COVERAGE

  • Alexion Pharmaceuticals, Inc. (ALXN)
  • Apellis Pharmaceuticals, Inc. (APLS)
  • Aptinyx Inc (APTX)
  • Ardelyx (ARDX)
  • Biogen, Inc. (BIIB)
  • Biohaven Pharmaceutical Holding Company LTD (BHVN)
  • Chinook Therapeutics, Inc. (KDNY)
  • Denali Therapeutics (DNLI)
  • Edgewise Therapeutics Inc (EWTX)
  • Impel NeuroPharma, Inc. (IMPL)
  • Karuna Therapeutics Inc. (KRTX)
  • Neurocrine Biosciences, Inc. (NBIX)
  • Passage Bio (PASG)
  • Praxis Precision Medicines, Inc. (PRAX)
  • Sage Therapeutics, Inc. (SAGE)
  • Stoke Therapeutics (STOK)
  • Taysha Gene Therapies (TSHA)
  • Travere therapeutice (TVTX)
  • Ultragenyx Pharmaceutical Inc (RARE)
  • Viridian Therapeutics, Inc. (MGEN)
  • Voyager Therapeutics Inc (VYGR)
  • Xenon Pharmaceuticals (XENE)